Dr. Randy Bateman highlights blood‑test accuracy and launches AI consortium to speed Alzheimer’s research

Dr. Randy Bateman, a neurology professor and director of the Dominantly Inherited Alzheimer’s Network (DIAN), told the council that advances in biomarkers and clinical trials have brought the field to a new, more preventive phase. "A single blood test has accuracies upwards of 90 to 95% accurate for identifying amyloid plaques," Bateman said, describing laboratory work that tracks phosphorylated tau and other molecules in blood.

The presentation placed those advances in historical context and explained why familial (dominantly inherited) Alzheimer’s families are valuable for research: predictable onset allows scientists to measure how pathology develops long before symptoms. Bateman showed DIAN data indicating amyloid plaques can appear roughly 20 years before symptoms and said long follow‑up of treated participants suggests clinically meaningful delay of dementia is possible for some individuals.

Bateman reviewed evidence from anti‑amyloid phase‑3 trials and long‑term extensions, saying drugs that markedly lower amyloid have shown clinical benefit. He described the DIAN‑2 amyloid removal trial, launched in 2024 and fully enrolled in its first year, and noted the study will continue at least five more years to determine the magnitude and durability of any protective effect. "Those who were treated the longest…could have 5 to 15 years [delay] of dementia," he said, noting modeling uncertainty about how familial results translate to sporadic Alzheimer’s.

Beyond biomarkers and trials, Bateman outlined C‑BRAIN (Consortia for Biomedical Research and Artificial Intelligence and Neurodegeneration), a collaborative effort that brings biomedical researchers, AI experts, pharma and philanthropies together to analyze massive datasets. He framed the consortium as a way to apply generative AI and deep neural networks to petabytes of complex biological data that are difficult for humans alone to synthesize.

Bateman closed by inviting council members and agency staff to learn more at cbrain.org and reiterated optimism that combining biomarkers, effective therapeutics and AI‑driven discovery could substantially change the course of Alzheimer’s disease in the coming decade.

The DIAN work Bateman described is supported by the National Institute on Aging, and the speaker emphasized continued longitudinal follow‑up and data sharing as next steps for both clinical trials and preventive strategies.